Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
about
Complement in the Homeostatic and Ischemic BrainThe exact science of stroke thrombolysis and the quiet art of patient selectionBryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic strokeMethodology for a community-based stroke preparedness intervention: the Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities Study.Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic strokeThrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model.Use of perfusion imaging and other imaging techniques to assess risks/benefits of acute stroke interventions.Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective.A comprehensive review of prehospital and in-hospital delay times in acute stroke care.Bringing the hospital to the patient: first treatment of stroke patients at the emergency site.Neurorestorative therapy for strokeEndovascular Management of Stroke Patients with Large Vessel Occlusion and Minor Stroke SymptomsRecombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial.Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms.Trends in thrombolytic use for ischemic stroke in the United States.Fibrinolysis and Beyond: Bridging the Gap between Local and Systemic Clot Removal.Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study.Race and sex disparities in prehospital recognition of acute stroke.External validation of the SEDAN score: The real world practice of a single center.Initial Stroke Severity Is the Major Outcome Predictor for Patients Who Do Not Receive Intravenous Thrombolysis due to Mild or Rapidly Improving Symptoms.Different Imaging Strategies in Patients With Possible Basilar Artery Occlusion: Cost-Effectiveness Analysis.Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment.Therapeutic hypothermia for stroke: do new outfits change an old friend?Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.Endovascular Therapy in Strokes with ASPECTS 5-7 May Result in Smaller Infarcts and Better Outcomes as Compared to Medical Treatment Alone.Myelin basic protein and ischemia modified albumin levels in acute ischemic stroke cases.Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) TrialEthnic disparities trump other risk factors in determining delay to emergency department arrival in acute ischemic strokeEndovascular management of acute ischemic stroke: advances in patient and treatment selection.Understanding the reasons behind the low utilisation of thrombolysis in strokeJoint commission primary stroke centers utilize more rt-PA in the nationwide inpatient sample.A call for formal telemedicine training during stroke fellowshipPredictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: multiple blood markers profiling study.Emergency Care of Patients with Acute Ischemic Stroke in the Kaiser Permanente Southern California Integrated Health System.Performance measures in neuroradiology.Systemic reperfusion therapy in acute ischemic stroke.Inability to consent does not diminish the desirability of stroke thrombolysis.
P2860
Q26796057-4191D72F-0ED9-4576-AA46-6B03F70B498AQ27011873-88A6CE96-CC36-4D83-AE63-E56CECE7CDCBQ28387089-EFEAF2F3-5528-4B21-AB2A-BB81B26EA6ABQ30209983-2B3BFE22-A782-40EB-A7C3-2BD110BC8E7AQ30414441-3C9A4CC3-6C02-4535-ABF5-4F5E5C93A201Q30448853-F3D628DA-2126-4B11-BD7E-B6ED0D622DA6Q30625019-FC76E283-9682-4C30-870B-07560DD2163EQ33600851-CA9F3C7E-E529-4151-A7D8-3F2D9D5C1D92Q33671817-DB64A508-A3B6-4A19-AB75-6AC08FC4320AQ33741926-30ED4AF4-CED3-4A58-BB36-3D410984DDDCQ33813333-43433A8E-9FBA-4A3B-80C6-D6B117061650Q33905200-0CF4D21F-791C-4581-A5B9-E25667323451Q33966207-746524C4-3FC7-4D36-BB4C-767EE6689169Q34036010-6E852E71-40B1-4218-ABE7-52B5586690BFQ34250891-FAC59B41-36CC-449C-BF01-090BE38685B5Q34262372-A95ED103-7F79-435E-B5EA-CA4F56CF682BQ34508464-ED5C94C3-5918-4A0E-BA5C-C76A6B9107D6Q34603396-F5FF8BE9-6540-4BED-BE64-32D3120E8BD8Q34679691-17115BFD-590E-4C2F-B618-D530111F9B07Q35143249-11A86926-2F52-4F39-9E9F-C18E736AC712Q35163608-26C4CA77-D189-4039-8DF8-8E0519F9D13CQ35651846-0B31E784-F7DB-45CF-ACD2-E580CB774C95Q35687311-35F618CC-3CB2-43BA-9042-ABDDE9B55EDBQ35767707-14F3B5B7-0828-4F71-BF51-249F72B00F98Q36048610-A0160D2F-C245-41AD-9FD6-09DAC327E7D4Q36106818-22EB6B40-509B-4774-BEE7-BE27800EDA02Q36227035-839AA00C-868B-4043-A982-BD5B76839C61Q36266779-2F9B35C6-7AAC-4F3D-A7B3-A142E26A4458Q36270112-CF73D0BE-5061-4FE1-A1B0-1A7F8E308154Q36476468-2D8A0E3B-D08F-4AAB-B211-CFE16F1F4CACQ36635107-C4DE7519-99F7-4F21-948D-D8DE6580CB56Q36730655-2043F07C-EF15-47A7-844C-B7A1875D6341Q36764851-E88DEA9E-A5E7-4132-879A-358842435D05Q36824775-C5DFE888-23B9-42FC-BEF6-583AE50B9762Q36887153-E9954E7E-E649-4360-BE3C-DBBCC2223D1BQ36902376-362D47C9-DEAC-4DEA-82F9-7401786F0049Q36903543-96EC1D11-0F88-41E0-9DE7-5847AA343148Q36936635-B6D0E0E7-0FC2-4015-9B97-F39BF2307BE2Q36986430-A8C1EF4A-62A8-42D9-9639-8775FE9B9BACQ37118649-8267CF33-C8FB-48D5-B06C-3BB2C2BCC283
P2860
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
@en
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
@nl
type
label
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
@en
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
@nl
prefLabel
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
@en
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
@nl
P2093
P1433
P1476
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
@en
P2093
Alex Abou-Chebl
Anthony J Furlan
Cleveland Clinic Health System Stroke Quality Improvement Team
Deborah M Nadzam
Eric D Hixson
Irene L Katzan
Maxim D Hammer
P304
P356
10.1001/ARCHNEUR.61.3.346
P577
2004-03-01T00:00:00Z